Cagrilintide 5mg

Cagrilintide is a synthetic peptide based on the human hormone amylin. Amylin is co-secreted with insulin by pancreatic beta cells and plays a role in glucose homeostasis and appetite regulation by acting on specific receptors in the brain. Cagrilintide is designed to mimic and potentially enhance the effects of natural amylin.

Researchers are investigating Cagrilintide primarily for its antidiabetic and anti-obesity properties. Studies in research models suggest it may reduce food intake, promote satiety, and facilitate modest weight loss, often in combination with other metabolic modulators. Its mechanism involves slowing gastric emptying and modulating glucagon secretion.

Mechanism of Action

Cagrilintide functions as a long-acting amylin analogue. It binds to and activates amylin receptors in areas of the brain involved in appetite control, such as the area postrema. This activation leads to a reduction in food intake and an increase in satiety. Additionally, Cagrilintide influences glucose metabolism by suppressing postprandial glucagon secretion and delaying gastric emptying, contributing to improved glycemic control.

Structure and Class

Cagrilintide is a peptide belonging to the amylin mimetic class. It is a synthetic analogue of the naturally occurring human hormone amylin. Its specific amino acid sequence and modifications confer improved pharmacological properties, such as increased half-life and potency, compared to native amylin, allowing for less frequent administration in research settings.

Primary Research Areas

In research, Cagrilintide is primarily studied for its effects on weight management, appetite regulation, and glucose control. Investigational studies explore its potential as a monotherapy or in combination with other metabolic agents, such as GLP-1 receptor agonists, to achieve enhanced metabolic benefits in preclinical models of obesity and diabetes.

Notable Peer-Reviewed Findings

Research published in journals like The Lancet has explored Cagrilintide's effects in research models, demonstrating significant weight reduction and improved glycemic parameters. A phase 2 trial, for example, showed that Cagrilintide, when administered weekly, led to a dose-dependent weight loss over several months. Further studies have indicated that combinations of Cagrilintide with GLP-1 receptor agonists may offer synergistic benefits for weight loss and metabolic health in investigational settings.